论文部分内容阅读
目的观察利喜定缓释剂(乌拉地尔-α1-受体阻滞剂)治疗轻、中度高血压病的疗效。方法对87例高血压患者采用随机、双盲、安慰剂对照的实验方法,随机分为治疗组44例,对照组43例进行对照观察。整个过程共7～8周,在整个过程中的所有入组患者进行1日2次血压测定,观察血压在整个治疗过程中的变化指征。结果在双盲治疗期末,利喜定组有效率为61%(27/44)。安慰剂组有效率为27.8%(12/43)(P=0.024)。结论利喜定具有双重降压作用,既作用于中枢神经系统,又作用于外周神经系统,在外周阻断了突触后α1A受体降低延髓心血管中枢而扩张血管,同时它可以兴奋中枢的5-羟色胺-IA受体,反馈调节而起降压作用。不会出现反馈性的心率增快,不干扰糖脂代谢,不引起水钠潴留,且患者耐受性好,不良反应轻,适用于各种类型高血压病的治疗。
Objective To observe the effect of li-xiding sustained-release agent (urapidil-α1-blocker) in the treatment of mild to moderate essential hypertension. Methods 87 patients with hypertension were randomized, double-blind, and placebo-controlled trial. They were randomly divided into treatment group (44 cases) and control group (43 cases). The whole process of a total of 7 to 8 weeks in the entire process of all patients into the group 2 times a day blood pressure was measured to observe changes in blood pressure throughout the course of treatment indications. Results At the end of the double-blind treatment period, the effective rate of lexedin was 61% (27/44). The placebo group was 27.8% (12/43) effective (P = 0.024). Conclusion Li Xidin has a dual antihypertensive effect, both acting on the central nervous system, but also on the peripheral nervous system, blocking the peripheral postsynaptic α1A receptor to reduce medulla oblongata cardiovascular center and dilate blood vessels, while it can excite the central Serotonin-IA receptor, feedback regulation and antihypertensive effect. Will not appear feedback faster heart rate, does not interfere with glucose and lipid metabolism, does not cause Shuinazhuliu, and patients with good tolerance, adverse reactions, suitable for the treatment of various types of hypertension.